Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of BRAF V600 mutant High Grade glioma that had relapsed, progressed or failed to respond to frontline therapy~* Diagnosis of BRAF V600 mutant Low Grade glioma with progressive disease following surgical excision, or non-surgical candidates with necessity to begin first systemic treatment because of a risk of neurological impairment with progression.~* Confirmed measurable disease~Key Exclusion Criteria:~* Previous treatment with dabrafenib, trametinib, other RAF inhibitor, other MEK or ERK inhibitor~* HGG patient: Cancer treatment within the past 3 weeks. LGG patient: Any systemic therapy or radiotherapy prior to enrollment~* LGG patients: history of allergic reaction or contraindications to the use of carboplatin or vincristine~* Stem cell transplant within the past 3 months~* History of heart disease~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- LGG cohort: dabrafenib and trametinib (Type: EXPERIMENTAL): Participants in the LGG cohort randomized to receive dabrafenib (orally, twice daily and dosed based on weight and age) in combination with trametinib (orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on weight)
- LGG cohort: carboplatin and vincristine (Type: ACTIVE_COMPARATOR): Participants in the LGG cohort randomized to receive active comparator chemotherapy (carboplatin and vincristine). Participants received one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy.
- HGG cohort: dabrafenib and trametinib (Type: EXPERIMENTAL): Participants in the HGG cohort received dabrafenib (orally, twice daily and dosed based on weight and age) and trametinib (orally, once daily in combination with the first daily dose of dabrafenib and dosed based on weight)

Based on this trial design, predict the completion outcome and termination type (if applicable).